InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Granted Patent for Innovative Treatment for MDD
December 10, 2020
VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new-generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, has been granted a patent by the Korean Intellectual Property Office (“KIPO”) for one of its treatments for depression. VistaGen received notification that KIPO […]
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Appointment of New VP of Translational Medicine
December 1, 2020
VistaGen Therapeutics (NASDAQ: VTGN) has appointed a new vice president of translational medicine. A pioneer in the development of neuroactive steroids known as pherines, Louis Monti, MD., PhD., developed the original scientific platform that enabled the early research and development of VistaGen’s PH94B and PH10. The two intranasal neuroactive steroid drug candidates (pherines) have potential […]
VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Positive Preclinical Data for Potential Anxiety Treatment
November 30, 2020
VTGN CEO “even more excited about PH94B’s potential to change lives without the risky side effects and safety concerns of benzos” Study results suggest PH94B’s mechanism of action may not have benzodiazepine-like side effects, such as sedation, cognitive impairment or abuse liability Company making significant progress in preparing PH94B for launch of pivotal Phase 3 […]
VistaGen Therapeutics (NASDAQ: VTGN) Seeks to Address Rising Incidence of Mental Health Disorders in United States
November 24, 2020
VistaGen currently developing three novel drug candidates designed to treat central nervous system disorders Anxiety disorders have been found to affect 18.1% of the U.S. population; however, only 36.9% of those suffering receive treatment Prevalence of depressive disorders in U.S. workplace is estimated to result in economic impact of over $210.5 billion per annum COVID-19 […]
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Q2 Results, Provides Update on CNS Pipeline and Business Progress
November 13, 2020
VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, today reported its financial results for the fiscal 2021 second quarter ended September 30, 2020. In addition, the company provided an update on its CNS pipeline and business progress. “We see a significant rise in […]
VistaGen Therapeutics Inc. (NASDAQ: VTGN) CEO Discusses ‘Game-Changing’ Potential of Drug Pipeline Lineup in Stock2Me Podcast
November 12, 2020
VTGN is committed to developing and commercializing differentiated new generation medications that go beyond the current standard of care for anxiety, depression and other CNS disorders. VTGN currently has three drugs in its pipeline, PH94B and PH10, both innovative synthetic neuroactive steroid nasal sprays, and AV-101, a novel, oral prodrug that targets the NMDAR. VTGN […]
InvestorNewsBreaks – VistaGen Therapeutics (NASDAQ: VTGN) Reports Positive Preclinical Data on PH94B’s Mechanism of Action
November 12, 2020
VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, today announced new in vitro electrophysiology data. According to the update, the data demonstrate that the mechanism of action of PH94B, the intranasal neuroactive steroid the company is preparing for Phase 3 development as a […]
VistaGen Therapeutics’ (NASDAQ: VTGN) New Generation Phase 3 Drug Candidate for Social Anxiety Disorder Gains Importance Amid FDA Wariness of Benzodiazepines
November 5, 2020
VistaGen has three innovative CNS drug candidates which target a wide range of anxiety, depression and neurological disorders PH94B, the Company’s most advanced drug candidate, is entering Phase 3 development for acute, on-demand treatment of social anxiety disorder Company sees potential to displace benzodiazepines currently being used to treat multiple anxiety disorders Strategy has gained […]
InvestorNewsBreaks – VistaGen Therapeutics (NASDAQ: VTGN) Featured in Stock2Me Podcast
November 3, 2020
VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, was featured in the latest episode of The Stock2Me Podcast, an InvestorBrandNetwork (“IBN”) solution to provide specialized content distribution via widespread syndication channels. The episode features Shawn K. Singh, CEO of VistaGen, as he discusses […]
VistaGen Therapeutics Inc. (NASDAQ: VTGN) Preclinical Study Data Show Drug Combo’s Innovative Potential in Fight Against Major Depressive Disorder
November 2, 2020
Study results have exciting therapeutic potential across wide range of CNS indications. VTGN focused on developing new generation of medications to treat anxiety, depression and more. Company committed to finding treatment to help estimated 264 million people around the world who suffer from depression. Noting that 17.3 million adults in the United States have had […]
InvestorNewsBreaks – VistaGen Therapeutics (NASDAQ: VTGN) Featured in BioWorld Article
October 30, 2020
VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, was featured in a recent BioWorld article titled, “CBC-funded Affamed merges with Everinsight, extends portfolio with Kissei PD candidate.” The publication discusses the merging of Affamed Therapeutics Ltd., an emerging biopharmaceutical company focused on […]